普羅布考片聯(lián)合阿托伐他汀鈣片與單用阿托伐他汀鈣片治療大動(dòng)脈粥樣硬化型腦梗死臨床療效的對(duì)比研究
發(fā)布時(shí)間：2018-08-03 08:55
【摘要】：目的比較普羅布考片聯(lián)合阿托伐他汀鈣片與單用阿托伐他汀鈣片治療大動(dòng)脈粥樣硬化型腦梗死患者的臨床療效。方法選取2012年1月—2015年5月威海市文登中心醫(yī)院神經(jīng)內(nèi)科收治的大動(dòng)脈粥樣硬化型腦梗死患者110例,隨機(jī)分為對(duì)照組與觀察組,每組55例。在常規(guī)治療基礎(chǔ)上,對(duì)照組患者予以阿托伐他汀鈣片治療,觀察組患者在對(duì)照組基礎(chǔ)上加用普羅布考片治療;兩組患者均連續(xù)治療6個(gè)月。比較兩組患者治療前后美國(guó)國(guó)立衛(wèi)生研究院卒中量表(NIHSS)評(píng)分、頸動(dòng)脈內(nèi)中膜厚度(IMT)及斑塊面積、血脂指標(biāo)〔總膽固醇(TC)、三酰甘油(TG)、低密度脂蛋白膽固醇(LDL-C)、高密度脂蛋白膽固醇(HDL-C)〕、血清氧化低密度脂蛋白(ox-LDL)和基質(zhì)金屬蛋白酶9(MMP-9)水平、不良反應(yīng)發(fā)生情況。結(jié)果治療前兩組患者NIHSS評(píng)分比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05);治療后觀察組患者NIHSS評(píng)分低于對(duì)照組(P0.05)。治療前兩組患者頸動(dòng)脈IMT、斑塊面積比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05);治療后觀察組患者頸動(dòng)脈IMT、斑塊面積小于對(duì)照組(P0.05)。治療前兩組患者血清TC、TG、LDL-C、HDL-C水平比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05);治療后觀察組患者血清TC、TG、LDL-C水平低于對(duì)照組(P0.05),而兩組患者血清HDL-C水平比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。治療前兩組患者血清ox-LDL、MMP-9水平比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05);治療后觀察組患者血清ox-LDL、MMP-9水平低于對(duì)照組(P0.05)。兩組患者不良反應(yīng)發(fā)生率比較,差異無統(tǒng)計(jì)學(xué)意義(P0.05)。結(jié)論普羅布考片聯(lián)合阿托伐他汀鈣片治療大動(dòng)脈粥樣硬化型腦梗死的臨床療效優(yōu)于單用阿托伐他汀鈣片,可更有效地改善患者神經(jīng)功能,縮小動(dòng)脈粥樣硬化斑塊,調(diào)節(jié)血脂代謝及降低血清ox-LDL、MMP-9水平,且安全性較高。
[Abstract]:Objective to compare the clinical effects of probucol tablets combined with Atto vastatin calcium tablets and Atto vastatin calcium tablets in the treatment of atherosclerotic cerebral infarction. Methods from January 2012 to May 2015 110 patients with atherosclerotic cerebral infarction were randomly divided into control group and observation group with 55 cases in each group. On the basis of routine treatment, the patients in the control group were treated with Atto vastatin calcium tablets, while the patients in the observation group were treated with probucol tablets on the basis of the control group, and the patients in both groups were treated continuously for 6 months. The (NIHSS) score, carotid intima-media thickness (IMT) and plaque area were compared between the two groups before and after treatment. Serum lipids (total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) high density lipoprotein cholesterol (HDL-C),) serum oxidized low density lipoprotein (ox-LDL) and matrix metalloproteinase 9 (MMP-9) were measured. Results there was no significant difference in NIHSS score between the two groups before treatment (P0.05), while the NIHSS score in the observation group was lower than that in the control group (P0.05). Before treatment, there was no significant difference in carotid IMT, plaque area between the two groups (P0.05); after treatment, the carotid IMT area in the observation group was smaller than that in the control group (P0.05). Before treatment, there was no significant difference between the two groups in the level of serum TCU TGG LDL-C (P0.05); after treatment, the level of TCU TGG LDL-C in the observation group was lower than that in the control group (P0.05), but there was no significant difference in the serum HDL-C level between the two groups (P0.05). Before treatment, there was no significant difference in the levels of serum ox-LDLMP-9 between the two groups (P0.05); after treatment, the level of serum ox-LDL- MMP-9 in the observation group was lower than that in the control group (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion Probucol tablets combined with Atto vastatin calcium tablets are more effective than Atto calcareous tablets in the treatment of atherosclerotic cerebral infarction, which can effectively improve the neurological function and reduce atherosclerotic plaques. It was safe to regulate the metabolism of blood lipid and to decrease the level of MMP-9 in serum ox-LDL.
【作者單位】： 山東省威海市文登中心醫(yī)院康復(fù)醫(yī)學(xué)科;山東省威海市文登中心醫(yī)院神經(jīng)內(nèi)科;山東省威海市文登中心醫(yī)院護(hù)理部;
【分類號(hào)】：R743.33
本文編號(hào)：2161240
[Abstract]:Objective to compare the clinical effects of probucol tablets combined with Atto vastatin calcium tablets and Atto vastatin calcium tablets in the treatment of atherosclerotic cerebral infarction. Methods from January 2012 to May 2015 110 patients with atherosclerotic cerebral infarction were randomly divided into control group and observation group with 55 cases in each group. On the basis of routine treatment, the patients in the control group were treated with Atto vastatin calcium tablets, while the patients in the observation group were treated with probucol tablets on the basis of the control group, and the patients in both groups were treated continuously for 6 months. The (NIHSS) score, carotid intima-media thickness (IMT) and plaque area were compared between the two groups before and after treatment. Serum lipids (total cholesterol (TC), triglyceride (TG), low density lipoprotein cholesterol (LDL-C) high density lipoprotein cholesterol (HDL-C),) serum oxidized low density lipoprotein (ox-LDL) and matrix metalloproteinase 9 (MMP-9) were measured. Results there was no significant difference in NIHSS score between the two groups before treatment (P0.05), while the NIHSS score in the observation group was lower than that in the control group (P0.05). Before treatment, there was no significant difference in carotid IMT, plaque area between the two groups (P0.05); after treatment, the carotid IMT area in the observation group was smaller than that in the control group (P0.05). Before treatment, there was no significant difference between the two groups in the level of serum TCU TGG LDL-C (P0.05); after treatment, the level of TCU TGG LDL-C in the observation group was lower than that in the control group (P0.05), but there was no significant difference in the serum HDL-C level between the two groups (P0.05). Before treatment, there was no significant difference in the levels of serum ox-LDLMP-9 between the two groups (P0.05); after treatment, the level of serum ox-LDL- MMP-9 in the observation group was lower than that in the control group (P0.05). There was no significant difference in the incidence of adverse reactions between the two groups (P0.05). Conclusion Probucol tablets combined with Atto vastatin calcium tablets are more effective than Atto calcareous tablets in the treatment of atherosclerotic cerebral infarction, which can effectively improve the neurological function and reduce atherosclerotic plaques. It was safe to regulate the metabolism of blood lipid and to decrease the level of MMP-9 in serum ox-LDL.
【作者單位】： 山東省威海市文登中心醫(yī)院康復(fù)醫(yī)學(xué)科;山東省威海市文登中心醫(yī)院神經(jīng)內(nèi)科;山東省威海市文登中心醫(yī)院護(hù)理部;
【分類號(hào)】：R743.33
【相似文獻(xiàn)】
相關(guān)期刊論文 前7條
1 向瑾;徐楠;余勤;王穎;梁茂植;苗佳;南峰;沈奇;秦永平;;普羅布考片單次口服給藥的人體藥物代謝動(dòng)力學(xué)研究[J];華西醫(yī)學(xué);2012年07期
2 張德祥,朱兆儀,許樹旭,溫建華;普羅布考片的臨床療效[J];中國(guó)新藥雜志;1998年01期
3 劉香;;普羅布考片合并荷丹片治療高脂血癥臨床觀察[J];內(nèi)蒙古中醫(yī)藥;2014年16期
4 冷靜;趙磊;李慧;;普羅布考片聯(lián)合復(fù)方地龍膠囊對(duì)頸動(dòng)脈粥樣硬化斑塊的影響[J];中國(guó)社區(qū)醫(yī)師(醫(yī)學(xué)專業(yè));2012年32期
5 孫成龍;梁浩;韓衍銀;李珂;齊永秀;;HPLC法同時(shí)測(cè)定阿托伐他汀鈣片與普羅布考片中2主分含量[J];中國(guó)藥房;2011年41期
6 邵衛(wèi);黃蓓;張忠文;陳國(guó)華;潘宋斌;;博心通膠囊治療頸動(dòng)脈不穩(wěn)定粥樣斑塊的療效觀察[J];湖北中醫(yī)雜志;2012年10期
7 ;[J];;年期
，本文編號(hào)：2161240
本文鏈接：http://sikaile.net/yixuelunwen/shenjingyixue/2161240.html
最近更新
教材專著
